Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lufotrelvir (PF-07304814) in Healthy Adults
NCT04627532Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Lufotrelvir with Placebo (2 arms). Primary endpoints: Treatment Emergent Treatment-Related Adverse Events at Day 32, Laboratory Test Findings of Potential Clinical Importance at Day 5 and 2 more. Started Oct 2020; status: completed.
02
Drugs
lufotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04627532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627532.